On September 1, INSILICO rose 5.49% in regular trading, trading at 46.1 HKD/share, with turnover of HKD 308 million, largely recovering from the decline triggered by its recent convertible bond issuance announcement.
On the news front, INSILICO was officially included in the MSCI Global Small Cap Index effective after market close on August 31, with passive tracking fund allocation demand providing support for the stock price. The company had previously announced on August 27 the issuance of USD 305 million in zero-coupon convertible bonds due 2027, with an initial conversion price of HKD 58.07 per share, representing a premium of approximately 23.5% over the closing price of HKD 47.02 on August 27. The potential equity dilution of approximately 7.07% had weighed on the stock.
Meanwhile, the company recently reported strong interim results, with revenue of USD 106 million for H1, up 287.2% year-over-year, and net profit of USD 35.5 million, achieving a turnaround from losses. Drug discovery and pipeline development revenue surged 331.3% to USD 103 million, driven by major licensing deals with global pharmaceutical companies.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments